Literature DB >> 17905176

Use of antidepressant medications during pregnancy: a multisite study.

Susan E Andrade1, Marsha A Raebel, Jeffrey Brown, Kimberly Lane, James Livingston, Denise Boudreau, Sharon J Rolnick, Douglas Roblin, David H Smith, Mary E Willy, Judy A Staffa, Richard Platt.   

Abstract

OBJECTIVE: This study was undertaken to provide information on the prevalence of use of antidepressant drugs among pregnant women in the United States. STUDY
DESIGN: A retrospective study was conducted using the automated databases of 7 health plans. Women who delivered an infant in a hospital were identified. Antidepressant drug use was evaluated assuming a gestational duration of 270 days.
RESULTS: Among the 118,935 deliveries occurring from 2001-2005, 6.6% of women were dispensed an antidepressant during pregnancy. Antidepressant drug use increased from 2.0% in 1996 to 7.6% of deliveries in 2004 and 2005. Selective serotonin reuptake inhibitor use increased from 1.5% in 1996 to 6.4% in 2004 and 6.2% in 2005.
CONCLUSION: Our finding that nearly 8% of pregnant women were prescribed antidepressants drugs during the years 2004 and 2005 highlights the importance of understanding the effects of these medications on the developing fetus and on the pregnant woman.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17905176     DOI: 10.1016/j.ajog.2007.07.036

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  129 in total

1.  Anatomical, physiological and metabolic changes with gestational age during normal pregnancy: a database for parameters required in physiologically based pharmacokinetic modelling.

Authors:  Khaled Abduljalil; Penny Furness; Trevor N Johnson; Amin Rostami-Hodjegan; Hora Soltani
Journal:  Clin Pharmacokinet       Date:  2012-06-01       Impact factor: 6.447

Review 2.  Investigating outcomes following the use of selective serotonin reuptake inhibitors for treating depression in pregnancy: a focus on methodological issues.

Authors:  Luke E Grzeskowiak; Andrew L Gilbert; Janna L Morrison
Journal:  Drug Saf       Date:  2011-11-01       Impact factor: 5.606

3.  Maternal antidepressant use and adverse outcomes: a cohort study of 228,876 pregnancies.

Authors:  Rachel M Hayes; Pingsheng Wu; Richard C Shelton; William O Cooper; William D Dupont; Ed Mitchel; Tina V Hartert
Journal:  Am J Obstet Gynecol       Date:  2012-04-30       Impact factor: 8.661

4.  Behavioural effects of fetal antidepressant exposure in a Norwegian cohort of discordant siblings.

Authors:  Ragnhild Eek Brandlistuen; Eivind Ystrom; Malin Eberhard-Gran; Irena Nulman; Gideon Koren; Hedvig Nordeng
Journal:  Int J Epidemiol       Date:  2015-04-14       Impact factor: 7.196

5.  The dynamic serotonin system of the maternal brain.

Authors:  Joseph S Lonstein
Journal:  Arch Womens Ment Health       Date:  2018-07-21       Impact factor: 3.633

6.  Perinatal Outcomes of Women Diagnosed with Attention-Deficit/Hyperactivity Disorder: An Australian Population-Based Cohort Study.

Authors:  Alison S Poulton; Bruce Armstrong; Ralph K Nanan
Journal:  CNS Drugs       Date:  2018-04       Impact factor: 5.749

7.  Examining the Reversibility of Long-Term Behavioral Disruptions in Progeny of Maternal SSRI Exposure.

Authors:  Susan E Maloney; Shyam Akula; Michael A Rieger; Katherine B McCullough; Krystal Chandler; Adrian M Corbett; Audrey E McGowin; Joseph D Dougherty
Journal:  eNeuro       Date:  2018-07-09

Review 8.  [Affective disorders during pregnancy : Therapy with antidepressants and mood stabilizers].

Authors:  N Bergemann; W E Paulus
Journal:  Nervenarzt       Date:  2016-09       Impact factor: 1.214

9.  The effects of maternal depression and use of antidepressants during pregnancy on risk of a child small for gestational age.

Authors:  Hans Mørch Jensen; Randi Grøn; Ojvind Lidegaard; Lars Henning Pedersen; Per Kragh Andersen; Lars Vedel Kessing
Journal:  Psychopharmacology (Berl)       Date:  2013-03-02       Impact factor: 4.530

10.  In utero exposure to selective serotonin reuptake inhibitors and risk for autism spectrum disorder.

Authors:  Nicole B Gidaya; Brian K Lee; Igor Burstyn; Michael Yudell; Erik L Mortensen; Craig J Newschaffer
Journal:  J Autism Dev Disord       Date:  2014-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.